Scientific Reports (May 2023)

Rapid TCR:Epitope Ranker (RAPTER): a primary human T cell reactivity screening assay pairing epitope and TCR at single cell resolution

  • Raquel P. Deering,
  • Lili Blumenberg,
  • Lianjie Li,
  • Ankur Dhanik,
  • Se Jeong,
  • Stephane Pourpe,
  • Hang Song,
  • Lauren Boucher,
  • Shoba Ragunathan,
  • Yanxia Li,
  • Maggie Zhong,
  • Jessica Kuhnert,
  • Christina Adler,
  • Peter Hawkins,
  • Namita T. Gupta,
  • Michael Moore,
  • Min Ni,
  • Johanna Hansen,
  • Yi Wei,
  • Gavin Thurston

DOI
https://doi.org/10.1038/s41598-023-35710-7
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Identifying epitopes that T cells respond to is critical for understanding T cell-mediated immunity. Traditional multimer and other single cell assays often require large blood volumes and/or expensive HLA-specific reagents and provide limited phenotypic and functional information. Here, we present the Rapid TCR:Epitope Ranker (RAPTER) assay, a single cell RNA sequencing (scRNA-SEQ) method that uses primary human T cells and antigen presenting cells (APCs) to assess functional T cell reactivity. Using hash-tag oligonucleotide (HTO) coding and T cell activation-induced markers (AIM), RAPTER defines paired epitope specificity and TCR sequence and can include RNA- and protein-level T cell phenotype information. We demonstrate that RAPTER identified specific reactivities to viral and tumor antigens at sensitivities as low as 0.15% of total CD8+ T cells, and deconvoluted low-frequency circulating HPV16-specific T cell clones from a cervical cancer patient. The specificities of TCRs identified by RAPTER for MART1, EBV, and influenza epitopes were functionally confirmed in vitro. In summary, RAPTER identifies low-frequency T cell reactivities using primary cells from low blood volumes, and the resulting paired TCR:ligand information can directly enable immunogenic antigen selection from limited patient samples for vaccine epitope inclusion, antigen-specific TCR tracking, and TCR cloning for further therapeutic development.